Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment
- PMID: 38578436
- PMCID: PMC11081051
- DOI: 10.20945/2359-4292-2022-0506
Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment
Abstract
Objective: Despite a favorable prognosis, some patients with papillary thyroid carcinoma (PTC) develop recurrence. The objective of this study was to examine the impact of the combination of initial American Thyroid Association (ATA) risk stratification with serum level of postoperative stimulated thyroglobulin (s-Tg) in predicting recurrence in patients with PTC and compare the results with an assessment of response to initial therapy (dynamic risk stratification).
Subjects and methods: We retrospectively analyzed 1,611 patients who had undergone total thyroidectomy for PTC, followed in most cases (87.3%) by radioactive iodine (RAI) administration. Clinicopathological features and s-Tg levels obtained 3 months postoperatively were evaluated. The patients were stratified according to ATA risk categories. Nonstimulated thyroglobulin levels and imaging studies obtained during the first year of follow-up were used to restage the patients based on response to initial therapy.
Results: After a mean follow-up of 61.5 months (range 12-246 months), tumor recurrence was diagnosed in 99 (6.1%) patients. According to ATA risk, recurrence was identified in 2.3% of the low-risk, 9% of the intermediate-risk, and 25% of the high-risk patients (p < 0.001). Using a receiver operating characteristic curve approach, a postoperative s-Tg level of 10 ng/mL emerged as the ideal cutoff value, with positive and negative predictive values of 24% and 97.8%, respectively (p < 0.001). Patients with low to intermediate ATA risk with postoperative s-Tg levels < 10 ng/mL and excellent response to treatment had a very low recurrence rate (<0.8%). In contrast, higher recurrence rates were observed in intermediate-riskto high-risk patients with postoperative s-Tg > 10 ng/mL and indeterminate response (25%) and in those with incomplete response regardless of ATA category or postoperative s-Tg value (38.5-87.5%). Using proportion of variance explained (PVE), the predicted recurrence using the ATA initial risk assessment alone was 12.7% and increased to 29.9% when postoperative s-Tg was added to the logistic regression model and 49.1% with dynamic risk stratification.
Conclusion: The combination of ATA staging system and postoperative s-Tg can better predict the risk of PTC recurrence. Initial risk estimates can be refined based ondynamic risk assessment following response to therapy, thus providing a useful guide for follow-up recommendations.
Keywords: Thyroid; papillary thyroid carcinoma; recurrence; risk assessment; thyroglobulin.
Conflict of interest statement
Disclosure: no potential conflict of interest relevant to this article was reported.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11081051/bin/2359-4292-aem-68-e220506-gf01.gif)
![Figure 2A](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11081051/bin/2359-4292-aem-68-e220506-gf02a.gif)
![Figure 2B](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11081051/bin/2359-4292-aem-68-e220506-gf02b.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11081051/bin/2359-4292-aem-68-e220506-gf03.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11081051/bin/2359-4292-aem-68-e220506-gf04.gif)
Similar articles
-
Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.Thyroid. 2010 Dec;20(12):1341-9. doi: 10.1089/thy.2010.0178. Epub 2010 Oct 29. Thyroid. 2010. PMID: 21034228 Free PMC article.
-
Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.Thyroid. 2021 Sep;31(9):1391-1399. doi: 10.1089/thy.2021.0209. Epub 2021 Aug 25. Thyroid. 2021. PMID: 34340593
-
Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma.BMC Endocr Disord. 2024 Jul 15;24(1):112. doi: 10.1186/s12902-024-01648-8. BMC Endocr Disord. 2024. PMID: 39004697 Free PMC article.
-
Static and dynamic prognostic factors of papillary thyroid carcinoma.Endocr J. 2014;61(12):1145-51. doi: 10.1507/endocrj.EJ14-0303. Epub 2014 Aug 7. Endocr J. 2014. PMID: 25100150 Review.
-
Risk Stratification in Differentiated Thyroid Cancer: An Ongoing Process.Rambam Maimonides Med J. 2016 Jan 28;7(1):e0003. doi: 10.5041/RMMJ.10230. Rambam Maimonides Med J. 2016. PMID: 26886959 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous